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Background. Chagas disease, caused by the parasite Trypanosoma cruzi, once considered a disease confined to Mexico, Central 
America, and South America, is now an emerging global public health problem. An estimated 300 000 immigrants in the United 
States are chronically infected with T. cruzi. However, awareness of Chagas disease among the medical community in the United 
States is poor.
Methods. We review our experience managing 60 patients with Chagas disease in hospitals throughout the New York City met-
ropolitan area and describe screening, clinical manifestations, EKG findings, imaging, and treatment.
Results. The most common country of origin of our patients was El Salvador (n = 24, 40%), and the most common detection 
method was by routine blood donor screening (n = 21, 35%). Nearly half of the patients were asymptomatic (n = 29, 48%). Twenty-
seven patients were treated with either benznidazole or nifurtimox, of whom 7 did not complete therapy due to side effects or were 
lost to follow-up. Ten patients had advanced heart failure requiring device implantation or organ transplantation.
Conclusions. Based on our experience, we recommend that targeted screening be used to identify at-risk, asymptomatic patients 
before progression to clinical disease. Evaluation should include an electrocardiogram, echocardiogram, and chest x-ray, as well as 
gastrointestinal imaging if relevant symptoms are present. Patients should be treated if appropriate, but providers should be aware of 
adverse effects that may prevent patients from completing treatment.
Keywords.  Chagas disease; heart transplant; New York City; nonendemic countries; Trypanosoma cruzi.
Chagas disease, caused by infection with the parasite 
Trypanosoma cruzi, was once considered a disease confined to 
poverty-stricken rural areas of Mexico, Central America, and 
South America. The World Health Organization currently esti-
mates that Chagas disease affects 6–7 million people and causes 
10000 deaths each year [1, 2]. The countries with the highest 
prevalence of Chagas disease are Bolivia, followed by Argentina, 
Paraguay, Ecuador, El Salvador, and Guatemala [3]. In endemic 
countries, most infections are acquired through vectorborne 
transmission by triatomine bugs [4]. Oral transmission can 
also occur when food or liquids contaminated with feces from 
infected triatomine bugs are consumed and is associated with 
outbreaks of acute Chagas disease [5]. In nonendemic coun-
tries, T.  cruzi can be transmitted through blood transfusion, 
organ transplantation, congenitally from mother to child, and, 
in rare cases, laboratory accidents [6, 7, 8, 9].
In the majority of cases, the acute phase of infection is never 
identified, and affected individuals are diagnosed with the in-
determinate form of chronic Chagas disease. Although most 
chronically infected individuals are asymptomatic and una-
ware of their infection, they remain potential sources of trans-
mission for the remainder of their life [10]. Roughly 20%–30% 
of chronically infected individuals progress to develop cardi-
omyopathy, and 10%–15% develop gastrointestinal involve-
ment [11, 12]. During the chronic phase, diagnosis is based on 
positive results from testing with 2 different serologic tests, for 
example, an enzyme-linked immunosorbent assay (ELISA) or 
immunofluorescence assay (IFA), preferably using 2 different 
antigen preparations [13, 14]. Published sensitivity and speci-
ficity of diagnostic tests range from 17% to 100% and 76% to 
100% respectively, but these estimates must be interpreted cau-
tiously due to geographic variation, heterogeneity in study de-
signs, and the lack of a gold standard [15, 16]. Two drugs are 
available for treatment, benznidazole and nifurtimox, although 
guidelines for treatment are not well established. The BENEFIT 
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trial, a randomized controlled trial of benznidazole vs pla-
cebo, showed no significant difference in clinical cardiac dis-
ease over 5.4 years of follow-up [17]. Antiparasitic treatment 
is generally not used in advanced heart failure, and these pa-
tients may require implantation of cardiac devices or organ 
transplantation [18].
In recent decades, the rate of emigration from Chagas-
endemic areas to the United States, Canada, Europe, Australia, 
and Japan has increased markedly and has changed the epi-
demiology of Chagas disease in these countries [19]. It is es-
timated that 23 million immigrants from endemic regions live 
in the United States and 300 000 of these persons are chroni-
cally infected by T. cruzi [20]. A screening program of >4000 
Latin American immigrants residing in the Los Angeles area 
found a Chagas disease prevalence of 1.24% [21]. The number 
of T. cruzi–infected immigrants and the possibility of transmis-
sion by nonvectorial mechanisms have turned Chagas disease 
into an emerging disease and a new public health problem in 
destination countries. Physicians caring for migrant patients 
need to become familiar with the diagnosis, complications, and 
indications for treatment of Chagas disease. This manuscript re-
views the experience managing 60 patients with Chagas disease 
in hospitals throughout the New York City metropolitan area.
METHODS
We performed a retrospective study extracting demographic 
and clinical information by manual chart review of patients 
diagnosed with Chagas disease who were evaluated between 
2005 and 2017 in major hospital systems in the New York City 
metropolitan area, defined as the 5 New York City boroughs 
and surrounding suburbs. Jacobi Medical Center (JMC) is a 
hospital in the New York City Health and Hospital Corporation 
and a major teaching facility of the Albert Einstein College of 
Medicine. It is the main facility treating Chagas disease patients 
through its Tropical Disease Clinic in the Bronx. Montefiore 
Medical Center (MMC) in the Bronx is the site of a large heart 
failure clinic and performs heart transplants, including trans-
plants in Chagas disease patients with end-stage heart failure. 
The Northwell-Hofstra University Medical Center is located on 
Long Island in suburban New York City. Patients were referred 
to the authors at these medical centers by physicians, family 
members, or the New York Blood Center.
Patients were diagnosed with chronic Chagas disease on 
the basis of serologic testing results. At the JMC Parasitology 
Laboratory, the Hemagen Chagas’ Enzyme Immunoassay Kit 
was used (Hemagen Diagnostics, Boston, MA, USA; sensi-
tivity, 88%–92%; specificity, 99%–100%) [15]. At MMC and 
Northwell, an ELISA was performed at a commercial lab (most 
commonly the Hemagen Chagas Kit at Quest Diagnostics, 
Inc.). At the Centers for Disease Control and Prevention 
(CDC), reference confirmatory testing was performed with 
the commercial Chagatest ELISA recombinante, version 3.0 
(Wiener Laboratorios, Argentina; sensitivity, 94%–97%; spec-
ificity, 97%–99%) [15], and an in-house IFA based on fixed 
epimastigotes (sensitivity, 94%; specificity, 95%) [22] until 2014. 
Thereafter, the in-house IFA was replaced with an in-house 
trypomastigote excreted-secreted antigens (TESA) immunoblot 
(sensitivity, 100%; specificity, 100%) [23]. When possible, family 
members of patients were also screened. Heart transplant recipi-
ents were tested preemptively for T. cruzi DNA approximately 
every 3 to 6 months after transplant to monitor for reactivation. 
Specimens were sent to the CDC, which employed an algorithm 
using 3 real-time polymerase chain reaction (PCR) assays with 
different targets run in parallel (individual PCR assay: sensitiv-
ities, 6%–78%; specificities, 40%–100%) [24].
The decision to initiate treatment was consistent with the 
practice of other experts and consensus groups [25, 26, 27]. In 
general, treatment was offered to patients without the following 
criteria: age >50 years, pregnancy, renal or hepatic dysfunction, 
or advanced heart disease. Treatment decisions could be indi-
vidualized and were at the discretion of the treating physician. 
All heart transplant recipients with reactivation Chagas dis-
ease were treated. Whether the patient received benznidazole 
or nifurtimox was based on drug availability per the CDC 
Investigational New Drug (IND) protocol. Patients receiving 
treatment were asked to follow up every 1–2 weeks to monitor 
for adverse events. Asymptomatic patients not on treatment 
were asked to follow up at least every 3–6 months, with closer 
follow-up if symptoms developed.
Patient demographic and clinical information was stored 
in a Microsoft Access (Seattle, WA, USA) database. This study 
was approved by the Institutional Review Board of the Albert 
Einstein College of Medicine and the Northwell-Hofstra 
University Medical Center.
RESULTS
Epidemiology
Sixty patients were included in the study, 30 males and 30 fe-
males. The mean age at diagnosis (SD) was 47 (15.65) years, 
ranging from 18 to 78  years. The plurality of patients (40%) 
were from El Salvador, followed by Mexico, Ecuador, Bolivia, 
Argentina, Brazil, Colombia, Guatemala, and Honduras 
(Figure 1). Of these, 5 patients were first-generation Americans 
born in the United States to immigrant parents, 3 from Bolivia 
and 2 from Argentina. There were 3 patients who did not fulfill 
all of the original criteria for confirmed infection but were nev-
ertheless included because of compelling clinical findings com-
patible with Chagas disease and risk history of T. cruzi infection. 
One was a 28-year-old woman with a positive ELISA at both 
JMC and the CDC from El Salvador. The second patient was 
a 78-year-old woman from the State of Minas Gerais in Brazil 
who had a positive ELISA performed at Quest Laboratories and 
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clinical findings of mega-esophagus and a right bundle-branch 
block (RBBB). The third patient was a 51-year-old woman born 
in Ecuador who had a positive ELISA performed at JMC and 
an RBBB.
Routine blood donor screening was the most common way 
patients with Chagas disease were first identified (n = 21, 35%). 
Seventeen patients were tested as part of evaluation for cardiac 
disease. Ten patients were screened due to a family history of 
Chagas disease. In 3 families, the index patient was detected 
upon blood donation screening. In 1 family, the index patient 
was among the 17 patients identified during evaluation of car-
diac disease. Nine patients were diagnosed as part of screening 
for endemic infectious diseases based on their country of or-
igin. Two patients were tested due to a report of positive testing 
as a child, and 1 due to complaint of gastrointestinal symptoms.
Clinical Manifestations and Evaluation
Nearly half of patients (n  =  29, 48%) were asymptomatic. 
Twenty-seven (45%) patients had cardiac manifestations in-
cluding heart failure and chest pain. Fourteen (23%) had gastro-
intestinal manifestations such as constipation, dysphagia, and 
abdominal pain. Patients reporting gastrointestinal symptoms 
were from El Salvador (n = 6), Ecuador (n = 3), Mexico (n = 2), 
Bolivia (n = ), and Brazil (n = 1). One patient had a suspected 
cardioembolic stroke from a cardiac apical aneurysm. Detailed 
symptoms are described in Table 1. Fourteen out of 29 (48%) 
asymptomatic patients had abnormal electrocardiogram (EKG) 
or imaging findings.
Out of 56 patients who had EKGs performed, 32 (57%) had 
abnormal findings. The most common abnormalities were 
RBBB (n  =  12, 21%), sinus bradycardia (n  =  12, 21%), and 
T-wave changes (n  =  12, 21%). There were 52 patients who 
had an echocardiogram performed, of whom 28 (54%) were 
abnormal. The most common echocardiogram abnormalities 
were tricuspid regurgitation (n = 17, 33%) and ventricular wall 
motion abnormalities, including hypokinesis, akinesis, and re-
gional wall motion abnormalities (n = 16, 31%). A representa-
tive EKG and echocardiogram are shown in Figure 2. Of the 41 
patients who had a chest x-ray performed, 12 (29%) had car-
diomegaly. Twenty-three patients had gastrointestinal imaging 
performed. The most common method of imaging was colon-
oscopy, followed by ultrasound, computed tomography, and 
esophagogastroduodenoscopy. Upper gastrointestinal series 
was performed in 4 patients. There was 1 patient with esopha-
geal dilatation, 2 patients with small intestine dilatation, and 1 
patient with megacolon. Both patients with esophageal dilata-
tion and megacolon were from Brazil. Other findings included 
gastritis (n = 4) and gall bladder thickening (n = 3). Table 2 de-
scribes specific EKG, echocardiogram, and chest x-ray findings 
broken down by presence of symptoms.
Treatment
In total, 27 patients were treated with either benznidazole 
or nifurtimox. Adverse effects were common, with 21 (78%) 
patients reporting at least 1 symptom. Despite the presence 
of adverse effects, 15 patients (71%) completed the full treat-
ment course. Of the 17 patients treated with benznidazole, 
5 (29%) did not complete therapy due to rash (n  =  5) with 
or without severe transaminitis (n  =  2). Of the 10 patients 
treated with nifurtimox, 2 (20%) did not complete therapy. 
One patient developed nausea and abdominal pain, and 1 pa-
tient was lost to follow-up. Characteristics and adverse effects 
Bolivia (7)
Ei Salvador (24)
Argentina (4)
Colombia (2)
Brazil (2)
Honduras (1)
Guatemala (1)
Ecuador (7)
Mexico (12)
Figure 1. Country of origin of Chagas disease patients (n = 60). Five patients were 
first-generation Americans born in the United States to Latin American immigrant 
parents and are included in this figure under their parents’ country of origin.
Table 1. Clinical Manifestations of Chagas Disease (n = 60); Patients May 
Report >1 Symptom so Numbers Sum to >100%
No. %
Asymptomatic 29 48
Cardiac 27 45
 Heart failure 16 27
 Chest pain 10 17
 Palpitations 8 13
 Dyspnea 5 8
Gastrointestinal 14 23
 Constipation 10 17
 Dysphagia 6 10
 Abdominal pain 5 8
 Heartburn 1 2
Neurologic 1 2
 Stroke 1 2
 Headache 1 2
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among patients receiving antitrypanosomal treatment are de-
scribed in detail in Table 3.
Ten patients had advanced heart disease requiring a pace-
maker (n = 1), implantable cardioverter defibrillator (n = 3), or 
left ventricular assist device (LVAD) (n = 6). One LVAD recip-
ient died while waiting for transplant, and the autopsy showed 
cardiomyocyte hypertrophy and fibrosis that were attributed to 
chronic Chagas disease. Six of the 10 patients received a heart 
transplant. Of these, 2 patients had reactivation of T. cruzi infec-
tion after transplant, as determined by T. cruzi PCR positivity, 
and were treated with benznidazole. One patient had graft re-
jection, and 1 had graft vasculopathy. Four patients were alive at 
2, 2.5, 4, and 7 years post-transplant. One died due to postoper-
ative complications, and 1 died from unrelated trauma.
DISCUSSION
To our knowledge, this is the largest case series describing the 
clinical experience of Chagas disease in the United States. Over 
a period of 12 years, we have cared for 60 patients. Most of the 
patients were referred to the tropical medicine clinic at Jacobi 
Medical Center, 1 of the few centers in New York City with ex-
perts in Chagas disease. Therefore the patients described in this 
series likely represent a significant portion of patients who have 
been diagnosed with Chagas disease in the region.
Similar to other studies from the United States, the most 
common country of origin was El Salvador, representing 
40% of patients. In a Los Angeles–based screening program, 
Salvadorans were 6.2 times more likely than other Latin 
American immigrants to test positive for Chagas disease [21]. 
Salvadorans also accounted for 72% of all Latin American pa-
tients who received benznidazole under the CDC IND protocol 
[28]. In contrast, Bolivia is frequently the most common country 
of origin in other nonendemic countries [29]. New York City 
is home to nearly 1 million Latin American immigrants, who 
account for the highest proportion (32%) of the city’s foreign-
born individuals. Of these, the largest number were born in the 
Dominican Republic, a country that is not endemic for Chagas 
disease. The largest number of foreign-born individuals in New 
York City from a Chagas-endemic country come from Mexico 
(186 298), followed by Ecuador (137 791), Colombia (65 678), El 
Salvador (32 903), and Honduras (28 552) [30, 31]. In our series, 
5 patients were born in the United States to immigrant parents, 
demonstrating the possibility of mother-to-child vertical trans-
mission within nonendemic countries, although transmission 
through other mechanisms due to shared epidemiologic risk 
cannot be ruled out.
Nearly half of our patients were asymptomatic. Despite the 
lack of overt symptoms, 48% of asymptomatic patients had 
abnormal EKG or imaging findings, underscoring the need 
for screening to identify patients before progression to clin-
ical disease. Blood donation was the most common reason for 
screening and would capture individuals who are infected but 
asymptomatic. In addition, our experience highlights the im-
portance of targeted screening in immigrants from endemic 
countries, particularly if cardiac or gastrointestinal symptoms 
are present. When a new diagnosis of Chagas disease is made, 
family members who share the same exposure history or were 
born to an infected mother should be tested as well [32]. Family-
based screening has also been used in other medical centers to 
effectively identify new cases, yielding a Chagas disease preva-
lence of 7.4% in a nonendemic setting [33] and as high as 42% 
in endemic settings [34].
A B
I aVR V1 V4
II
II
aVL V2 V5
III
V1
V5
aVF V3 V6
25 mm/s 10 mm/mV 40Hz
Figure 2. A, Representative electrocardiogram demonstrating sinus bradycardia, first-degree atrioventricular block, low voltage, T-wave changes, and right bundle 
branch block. B, Representative transthoracic echocardiogram 4-chamber view demonstrating severe left ventricular dilatation and moderate right ventricular dilatation. 
Abbreviations: LV, left ventricle; RV, right ventricle.
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In keeping with expert opinion [25, 26, 27], we recommend 
that the evaluation of Chagas disease include an EKG, echo-
cardiogram, and chest x-ray. These studies may be able to de-
tect subclinical cardiac involvement, such as sinus bradycardia, 
RBBB, and wall motion abnormalities. Among our patients, 57% 
had abnormal EKGs and 54% had abnormal echocardiograms, 
compared with 31.5% and 5.6%, respectively, in a study of 485 
Chagas disease patients in Spain [35]. Additionally, 27% of our 
patients developed heart failure, compared with only 2.6% in 
the Spanish study. The higher prevalence of cardiac disease and 
abnormal cardiac evaluation in our study can be explained by 
recruitment bias introduced from the fact that 1 of the treat-
ment sites is a center for heart failure and transplantation.
Gastrointestinal disease is more common in patients from 
the southern cone of South America (Brazil, Argentina, Bolivia, 
Chile, and Paraguay) [36]. However, in our series patients 
endorsing gastrointestinal symptoms were predominantly from 
Mexico and Central America, possibly reflective of the fact 
Table 2. EKG, Echocardiogram, and Chest X-ray Findings in Chagas Disease; Patients May Have >1 Abnormality so Numbers Sum to >100%
EKG Findings
Asymptomatic Symptomatic Total
 (n = 25) (n = 31) (n = 56) %
Normal 16 8 24 43
Right bundle branch block 3 9 12 21
Sinus bradycardia 5 7 12 21
T wave changes 1 11 12 21
Premature atrial or ventricular contractions 2 9 11 20
Low voltage 1 6 7 13
Left axis deviation 0 6 6 11
First-degree AV block 0 5 5 9
Left bundle branch block 0 5 5 9
Atrial fibrillation 0 5 5 9
Prolonged QT 0 1 1 2
Left ventricular hypertrophy 1 0 1 2
Left atrial enlargement 0 1 1 2
Echocardiogram Findings
 Asymptomatic Symptomatic Total
 (n = 21) (n = 31) (n = 52) %
Normal 16 8 24 46
Ventricular abnormalities
 Wall motion abnormalities 0 16 16 31
 Systolic dysfunction 0 13 13 25
 Left ventricle dilatation 1 9 10 19
 Left ventricle aneurysm 0 5 5 10
 Right ventricle dilatation 1 3 4 8
 Diastolic dysfunction 2 2 4 8
Atrial abnormalities
 Left atrial dilatation/enlargement 2 9 11 21
 Right atrial dilatation 1 2 3 6
 Atrial septal aneurysm 1 1 2 4
 Increased left atrial pressure 0 2 2 4
Valvular abnormalities
 Tricuspid regurgitation 1 16 17 33
 Mitral regurgitation 2 13 15 29
 Aortic regurgitation 1 7 8 15
 Pulmonary regurgitation 0 4 4 8
 Mitral stenosis 0 1 1 2
Pulmonary hypertension 0 4 4 8
Pericardial effusion 0 4 4 8
Chest X-ray Findings
 Asymptomatic Symptomatic Total
 (n = 14) (n = 27) (n = 41) %
Cardiomegaly 1 11 12 29
Abbreviations: AV, atrioventricular; EKG, electrocardiogram; QT, interval from start of the Q wave to the end of the T wave.
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that subjective symptoms are nonspecific for Chagasic gastro-
intestinal disease. Imaging findings of dilated esophagus and 
megacolon, findings more specific for Chagasic gastrointes-
tinal disease, were present in 2 patients from Brazil. Therefore, 
to evaluate for Chagasic gastrointestinal disease, we recom-
mend that imaging be performed if any relevant complaints are 
present.
When appropriate, patients were treated with either 
benznidazole or nifurtimox based on drug availability through 
the CDC. After the study period, benznidazole was FDA ap-
proved and, as of May 2018, has been commercially available 
[28]. Benznidazole is now generally considered first-line therapy 
due to better tolerability, although both benznidazole and 
nifurtimox are associated with high rates of adverse effects [27]. 
Benznidazole most commonly produces dermatologic effects, 
such as rash, edema, and itching. Gastrointestinal (eg, nausea, 
abdominal pain, anorexia) and neurologic (eg, headache, neu-
ropathy, insomnia) symptoms are also frequently reported [37, 
38, 39]. Nifurtimox most commonly causes gastrointestinal and 
neurologic symptoms; dermatologic symptoms are uncommon 
[40, 41]. In our series, the prevalence of adverse effects was 
high overall (78%), and the effects reported for benznidazole 
and nifurtimox were similar to those described in the litera-
ture. The majority of adverse effects were minor and did not 
require discontinuation of therapy. The discontinuation rate 
was 29% among patients treated with benznidazole (compared 
with 13%–30% reported in the literature) [17, 37, 38, 39] and 
20% among patients treated with nifurtimox (compared with 
20%–44% in the literature) [41, 42], although the number of 
treated patients was small.
Patients with advanced heart disease were not offered 
antiparasitic treatment, as treatment would not alter clinical 
outcomes. In some cases, Chagasic heart disease was severely 
advanced to the point of requiring implantable devices or trans-
plantation. Limited evidence suggests that post-transplant 
outcomes in Chagas disease patients are comparable to the out-
comes of patients with heart failure from other causes [13], but 
further evaluation is warranted. Similar to observations from 
other US transplant centers [42], Chagas reactivation was a 
significant concern in our heart transplant recipients. Risk of 
reactivation is highest in the first 2 years post-transplant, and 
highest for transplantation of hearts compared with other solid 
organs [43]. In accordance with expert consensus, our trans-
plant patients were monitored routinely with PCR, and those 
with detectable parasitemia were treated. Prophylactic treat-
ment is not recommended [44–45]. Donor-derived infection, 
that is, transmission from a T. cruzi–infected donor to an un-
infected recipient, was not present in this case series, though 
it has been described in the United States [46–48]. Current 
consensus guidelines recommend targeted screening of donors 
born in endemic countries. Transplantation of kidney or liver 
from a T. cruzi–infected donor is acceptable with informed con-
sent, frequent parasitological monitoring post-transplant, and 
immediate treatment if infection is detected. Heart transplants 
from infected donors should be avoided [46].
In an era of increased migration, Chagas disease is emerging 
as an important public health issue worldwide. Latin Americans 
represent the largest foreign-born population in the New York 
City metropolitan area and in the United States [30]. However, 
the medical community in the United States has little awareness 
or experience with Chagas disease [49–50]. Most infected per-
sons are asymptomatic and go undiagnosed, but Chagas disease 
can progress to severe heart disease and even death. Increased 
awareness of risk factors and clinical manifestations of Chagas 
disease is necessary to identify and treat patients early.
Limitations
This is a retrospective study that describes patients limited 
to the practice of the authors and may not be representative 
of other settings. Additionally, we describe only patients who 
presented to our hospitals, including some referred by family 
Table 3. Characteristics and Adverse Effects of Patients Receiving 
Antitrypanosomal Therapy (n = 27)
 
Benznidazole 
(n = 17)
Nifurtimox 
(n = 10) Overall (n = 27)
Age, median  
(range), y
36 (26–52) 31 (23–44) 36 (23–52)
Female, No. (%) 9 (53) 4 (40) 13 (48)
Asymptomatic, No. 
(%)
12 (71) 5 (50) 17 (63)
Completed treatment,  
No. (%)
12 (71) 8 (80) 20 (74)
Experienced adverse  
effects, No. (%)
13 (76) 8 (80) 21 (78)
Gastrointestinal 6 (35) 7 (70) 13 (48)
 Abdominal pain 1 (6) 6 (60) 7 (26)
 Anorexia 0 (0) 2 (20) 2 (7)
 Heartburn 0 (0) 0 (0) 0 (0)
 Nausea 2 (12) 4 (40) 6 (22)
 Transaminitis 4 (24) 0 (0) 4 (15)
Dermatologic 7 (41) 2 (20) 9 (33)
 Rash 7 (41) 2 (20) 9 (33)
 Edema 2 (12) 0 (0) 2 (7)
 Pruritis 0 (0) 1 (10) 1 (4)
Neurologic/ 
neuropsychiatric
3 (18) 5 (50) 8 (30)
 Headache 0 (0) 4 (40) 4 (15)
 Sleep disturbance 2 (12) 2 (20) 4 (15)
 Memory loss 0 (0) 1 (10) 1 (4)
 Anxiety 0 (0) 1 (10) 1 (4)
 Peripheral neurop-
athy
2 (12) 1 (10) 3 (11)
 Lightheadedness 0 (0) 2 (20) 2 (7)
Myalgias 0 (0) 2 (20) 2 (7)
Palpitations 0 (0) 1 (10) 1 (4)
Fatigue 0 (0) 1 (10) 1 (4)
Lost to follow-up 0 (0) 1 (10) 1 (4)
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members, private physicians, and the New York Blood Center, 
which excludes those with limited access to care. One patient 
was lost to follow-up. Symptoms reported or test results may 
not be related to Chagas disease, and tests may have been per-
formed for reasons other than evaluation of Chagas disease. 
Due to the fact that patients were identified by referral, we are 
unable to determine prevalence in our hospitals or communi-
ties. A prior study found the prevalence of Chagas disease to 
be 0.008% among the New York City metropolitan area blood 
donor population, which was the most common source of re-
ferral for our patients [51].
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